Qube Research & Technologies LTD Alector, Inc. Transaction History

Qube Research & Technologies LTD

  • $62.3 Billion
  • Q2 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$5.69 - $8.08 $106,909 - $151,815
18,789 New
18,789 $113,000
Q2 2022

Aug 15, 2022
SELL
$7.65 - $14.24 $326,792 - $608,304
-42,718 Reduced 56.78%
32,518 $330,000
Q1 2022

May 09, 2022
BUY
$13.02 - $20.78 $611,614 - $976,140
46,975 Added 166.22%
75,236 $1.07 Million
Q4 2021

Feb 01, 2022
BUY
$19.35 - $25.54 $546,850 - $721,785
28,261 New
28,261 $584,000
Q4 2020

Feb 16, 2021
SELL
$9.4 - $16.7 $103,691 - $184,217
-11,031 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$10.54 - $24.96 $116,266 - $275,333
11,031 New
11,031 $116,000

Others Institutions Holding ALEC

# of Institutions
165
Shares Held
58.1M
Call Options Held
57K
Put Options Held
14.9K
View Full List

About Alector, Inc.

ALEC Quotes by TradingView
  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $386M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email